Emerging infectious diseases continue to be of a significant importance worldwide with the potential to cause major outbreaks and global pandemics. In 2002, the world had witnessed the appearance of the severe acute respiratory syndrome coronavirus in China which disappeared abruptly within 6 months. About a decade later, a new and emerging novel coronavirus named the Middle East respiratory syndrome coronavirus (MERS-CoV) was described in a patient from Saudi Arabia. These two coronaviruses shared multiple similarities in the epidemiology, clinical presentations, and posed challenges in prevention and management. Seven years since its discovery, MERS-CoV continues to be a lethal zoonotic pathogen capable of causing severe pneumonia with high case fatality rates and the ability to cause large health care-associated outbreaks.

The SARS-CoV and MERS-CoV

SARS-CoV and MERS-CoV are enveloped positive strand RNA betacoronaviruses. The first coronavirus was isolated from humans in 1965 and was cultivated on human ciliated embryonal tracheal cells. Coronaviruses are enveloped, and positive stranded RNA viruses classified as a family within the Nidovirales order. There are four genera: α, β, gamma, and delta, and human coronaviruses belong to the α or the β genera. In 2002, SARS-CoV outbreak was described and the virus was 50 to 60% identical and distantly related to known coronaviruses. The newly described virus was able...
to cause disease in macaques with a similar spectrum of disease.\textsuperscript{1,2} While the MERS-CoV belongs to lineage C beta-coronavirus and emerged in September 2012 and continuous to cause sporadic cases and clusters of disease mostly in the Arabian Peninsula.\textsuperscript{13}

**SARS Outbreak Evolution and Clinical Characteristics**

The initial description of the SARS outbreak was announced in November 2002 through non-official reports of the occurrence of an outbreak of respiratory illness in Guangdong Province, China,\textsuperscript{14} and few months later, this was reported to the World Health Organization (WHO). Analysis of the virus showed a point-source outbreak.\textsuperscript{15} The disease was recognized due to the occurrence of a cluster of atypical pneumonias occurring in Vietnam, Hong Kong, Canada, United States, and Singapore.\textsuperscript{1,16–23} All cases were linked to a patient who stayed in hotel M in Hong Kong, and subsequently, patients traveled from Hong Kong to Ireland, Vietnam, Singapore, United States, and Canada.\textsuperscript{24} This outbreak involved 30 countries in 6 continents and caused a total of 8,098 cases with a case fatality rate of 9.5%.\textsuperscript{25} The clinical spectrum of the disease ranged from mild to severe disease requiring mechanical ventilation.\textsuperscript{26} The clinical picture followed an initial febrile illness, followed by a period of improvement then a clinical deterioration.\textsuperscript{27–29} The need for intensive care unit (ICU) care was described in 17 to 30% of SARS patients.\textsuperscript{28–30} In another study, 15% of SARS patients required mechanical ventilation.\textsuperscript{27} Patients also had extra-respiratory symptoms such as diarrhea.\textsuperscript{31} It was interesting to note that health care workers (HCWs) constituted 21% of all SARS cases.\textsuperscript{32–34} The disease was associated with 10% case fatality rate,\textsuperscript{35} and the presence of diabetes mellitus and other comorbidities was associated with increased fatality rates.\textsuperscript{30} SARS was thought to cause milder disease in children with no fatalities.\textsuperscript{36} One reason for the rapid spread of SARS was the occurrence of superspreaders.\textsuperscript{35} Superspreading event is described as the ability of certain individuals to infect a disproportionately large number of secondary patients relative to a typical infectious individual.

The origin of the SARS virus is thought to be animal and a similar virus was isolated from Himalayan palm civets (*Paguma larvata*), raccoon dogs (*Nyctereutes procyonoides*), and from a Chinese ferret badger (*Melogale moschata*).\textsuperscript{37} In addition, antibodies against SARS-CoV were found among individuals with trading history involving *P. larvata*.\textsuperscript{38} Although most patients with SARS had symptomatic disease, there are few seroprevalence studies and one study showed that 124 (12%) of 1,030 individuals were positive by ELISA and 0.19% by the SARS-specific immunofluorescence assay (IFA).\textsuperscript{39} In another study, seroprevalence among HCWs was 2.3%\textsuperscript{40} and a meta-analysis showed an overall seroprevalence of 0.10%.\textsuperscript{41} There were no approved therapeutic or preventative options for SARS, while a variety of therapeutic agents were used.\textsuperscript{42} SARS human cases disappeared abruptly by June 2003 with no approved vaccine or therapeutic agents developed or applied.

**MERS-CoV Evolution and Origin of the Virus**

The first case of MERS-CoV was reported in a businessman who lived in Bisha, Kingdom of Saudi Arabia (KSA) who presented to health care with pneumonia in early June 2012 and on transfer to a hospital in Jeddah, he rapidly succumbed to death within 10 days of diagnosis with multiorgan failure. The virus was later isolated and reported in September 2012 as the newly emerging MERS-CoV. As of January 2020, there have been a total of 2,468 cases of human MERS-CoV cases reported to WHO from 27 countries. More than 80% of cases have been reported from the Arabian Peninsula with KSA being the most affected country. There have been 851 reported mortalities with an overall case fatality rate of MERS-CoV estimated at 35% (Fig. 1). The exact origin of MERS-CoV is not known. However, MERS-CoV is likely to have originated from bats based on the isolation of other lineage C β-coronaviruses closely related to MERS-CoV and the isolation of a bat coronavirus that resembles MERS-CoV. Throat swabs, urine, feces, and serum samples were collected from wild bats in the KSA including the area where the first MERS-CoV patient had lived and worked. A 190-nucleotide fragment of the RNA-dependent RNA polymerase region of MERS-CoV genome was detected in one fecal pellet from an Egyptian tomb bat (*Taphozous perforates*).\textsuperscript{42} The amplified sequence was identical to that of the MERS-CoV sequence from the first index human case.\textsuperscript{31} The one-humped dromedaries (*Camelus dromedarius*) had been linked to MERS-CoV (Fig. 2). Multiple studies showed high prevalence of MERS-CoV antibodies in dromedary camels in the Arabian Peninsula, North Africa, and Eastern Africa.\textsuperscript{44–50} In addition, studies have shown that MERS-CoV antibodies were present in stored camel sera as early as early 1990s, suggesting the presence of MERS-CoV in dromedaries for over 20 years before its first description in humans.\textsuperscript{50–52} MERS-CoV antibodies were detected more commonly among camels > 2 years of age compared with younger camels.\textsuperscript{46,52–54} In addition, MERS-CoV was detected from respiratory tract samples by reverse transcriptase polymerase chain reaction (RT-PCR) in oronasal and fecal samples from dromedary camels in the Arabian Peninsula.\textsuperscript{52–58} In contrast to the MERS-CoV antibodies, juvenile camels shed more MERS-CoV as detected by PCR.\textsuperscript{52–55} In addition, viable MERS-CoV was isolated in cell cultures from nasal and fecal samples from dromedary camels in the Arabian Peninsula.\textsuperscript{52–58} The one-humped dromedary (*Camelus dromedarius*), and from a Chinese ferret badger (*Melogale moschata*).\textsuperscript{37} In addition, antibodies against SARS-CoV were found among wild animal traders in Guangdong Province.\textsuperscript{37,38} A seroprevalence of 72.7% was well known among those with trading history involving *P. larvata*.\textsuperscript{38} Although most patients with SARS had symptomatic disease, there are few seroprevalence studies and one study showed that 124 (12%) of 1,030 individuals were positive by ELISA and 0.19% by the SARS-specific immunofluorescence assay (IFA).\textsuperscript{39} In another study, seroprevalence among HCWs was 2.3%\textsuperscript{40} and a meta-analysis showed an overall seroprevalence of 0.10%.\textsuperscript{41} There were no approved therapeutic or preventative options for SARS, while a variety of therapeutic agents were used.\textsuperscript{42} SARS human cases disappeared abruptly by June 2003 with no approved vaccine or therapeutic agents developed or applied.

The clinical and laboratory presentations of SARS-CoV and MERS-CoV are similar with some minor differences highlighted in Table 1. The clinical picture of MERS-CoV cases ranges from asymptomatic to severe cases. In many cases, the presenting
symptoms are respiratory and 33% of patients have gastrointestinal symptoms such as vomiting and diarrhea. Most hospitalized MERS-CoV patients present with fever, cough, and shortness of breath with clinical and radiological evidence of pneumonia. It seems that severe disease is a characteristic of primary cases, immunocompromised, and those with underlying comorbidities namely diabetes, kidney, and heart disease. In severe cases, there are multiple complications including respiratory and renal failure, acute liver injury, cardiac arrhythmias, and coagulopathy. There are few studies which showed no predictive signs or symptoms to differentiate patients with community-acquired pneumonia from those with MERS-CoV infection. The median incubation period was 5.2 days (95% confidence interval [CI], 1.9–14.7), and the serial interval was 7.6 days (95% CI, 2.5–23.1). The median time to hospitalization, ICU admission, mechanical ventilation, and death were 5, 7, and 11 days, respectively. MERS-CoV carries a high case fatality rate (28.6–63.6%) specially among elderly patients with several comorbidities, while in young healthy patients, they present with mild to no symptoms. One study found a lower case fatality rate similar to the rate reported in patients from South Korea of 9%. The variability of the case fatality rates may be related to host factors, associated comorbidities, care provided, and yet unidentified factors. In addition, the case fatality rate is inversely related to the percentage of asymptomatic cases as the percentage of these patients increased to 29%, and the case fatality rate decreased to 30%. In KSA, extensive testing for MERS-CoV is being done over the past 6 years with >50,000 patients presenting to emergency care with respiratory symptoms being screened for MERS-CoV each year with a very low yield of 0.7% being positive. This excessive testing is applied in combination with a visual triage in all emergency rooms of all health care facilities (governmental and private) utilizing a clinical score cutoff of >4 for MERS-CoV infection showing sensitivity and specificity of 74.1 and 18.6%, respectively, in predicting MERS-CoV diagnosis. Predictors of 30-day mortality included factors such as age >65 years, being a non-HCW, the presence of preexisting comorbidities, presentation with severe disease, hospital-acquired infections, and corticosteroid use. The use of continuous renal replacement therapy and extracorporeal membrane oxygenation (ECMO) were additional risk factors for increased fatality. However, one study showed ECMO lowering in-hospital death.

**Fig. 1** Epicurve of confirmed global cases of MERS-CoV from September 2012 to July 16, 2019. MERS-CoV, Middle East respiratory syndrome coronavirus; WHO, World Health Organization.

**Fig. 2** Camels: a possible intermediary source of Middle Eastern respiratory syndrome coronavirus.
Table 1  Comparison of demographic, clinical, and laboratory features between MERS-CoV and SARS-CoV

|                                | MERS-CoV\(^{8,36-39}\) | SARS-CoV\(^{1,28,40}\) |
|--------------------------------|-------------------------|-------------------------|
| Date of first case report (place) | April 2012 (Jordan)  | November 2002 (China)   |
| Incubation period               | Mean: 5.2 d (95% CI: 1.9–14.7)  | Mean: 4.6 d (95% CI: 3.8–5.8)  |
| Range: 2–13 d                   | Range: 2–14 d            |                         |
| Serial interval                 | 7.6 d                   | 8.4 d                   |
| Age group                       |                         |                         |
| Adults                          | 98%                     | 93%                     |
| Children                        | 2%                      | 5–7%                    |
| Age (y): range, median          | Range: 1–94; median: 50 | Range: 1–91; mean: 39.9 |
| Mortality                       |                         |                         |
| CFR—overall                     | 41.8%                   | 9.6%                    |
| CFR in patients with comorbidities | 13.3%                | 1–2%                    |
| Time from onset to death        | Median 11.5 d           | Mean 23.7 d             |
| Sex (M, F)                      | M: 64.5%, F: 35.5%      | M: 43%, F: 57%          |
| Presenting symptoms             |                         |                         |
| Fever >38°C                     | 98%                     | 99–100%                 |
| Chills/rigors                   | 87%                     | 15–73%                  |
| Cough                           | 83%                     | 62–100%                 |
| Dry                             | 56%                     | 29–75%                  |
| Productive                      | 44%                     | 4–29%                   |
| Hemoptysis                      | 17%                     | 0–1%                    |
| Headache                        | 11%                     | 20–56%                  |
| Myalgia                         | 32%                     | 45–61%                  |
| Malaise                         | 38%                     | 31–45%                  |
| Shortness of breath             | 72%                     | 40–42%                  |
| Nausea                          | 21%                     | 20–35%                  |
| Vomiting                        | 21%                     | 20–35%                  |
| Diarrhea                        | 26%                     | 20–25%                  |
| Sore throat                     | 14%                     | 13–25%                  |
| Rhinorrhea                      | 6%                      | 2–24%                   |
| Comorbidities                   | 76%                     | 10–30%                  |
| Diabetes                        | 10%                     | 24%                     |
| Chronic renal disease           | 13%                     | 2–6%                    |
| Chronic heart disease           | 7.5%                    | 10%                     |
| Malignancy                      | 2%                      | 3%                      |
| Hypertension                    | 34%                     | 19%                     |
| Obesity                         | 17%                     | N/A                     |
| Smoking                         | 23%                     | 17%                     |
| Viral hepatitis                 | Not known               | 27%                     |
| Laboratory results              |                         |                         |
| CXR abnormalities               | 100%                    | 94–100%                 |
| Lymphopenia (<1.5 × 10^9/L)     | 32%                     | 68–85%                  |
| Leukopenia (<4.0 × 10^9/L)      | 14%                     | 25–35%                  |
Laboratory Tests
The diagnosis of MERS-CoV infection relies on the confirmation by real-time reverse transcriptase PCR of respiratory tract samples. Lower respiratory samples provide better yield and is the sample source of choice for testing. However, a single negative test should not rule out infection and a repeat testing is indicated as some patients may have intermittent positive tests. Serologic testing for MERS-CoV utilizes IFA, serum neutralization, or protein microarray assays to detect MERS-CoV antibodies. The utility of serodiagnosis relies on two serum samples taken 14 days or more apart. Serodiagnosis begins with a screening ELISA or IFA and a confirmatory neutralization assay. Testing for MERS-CoV by PCR detected the virus in the patient serum, urine, and feces but at a much lower level than those found in the lower respiratory tract. Patients with MERS-CoV infection had abnormal laboratory findings including: leukopenia, lymphopenia, thrombocytopenia, and elevated hepatic enzymes. A risk analysis showed that the following were associated with increased risk of death: presence of comorbidity (relative risk [RR] = 3), male gender (RR = 1.6), exposure to dromedary camels (RR = 1.6), and consumption of camel milk (RR = 1.5). Overall, over the past 7 years, 50% of MERS-CoV cases reported to WHO were associated with human-to-human transmission in hospitals. Among 61 MERS-CoV patients presenting with MERS-CoV in 2017, 9 (15%) were associated with a hospital outbreak, 10 (16%) were household contacts, and 42 (69%) were sporadic cases. Of the 42 sporadic cases, 50% had camel contact. In an outbreak investigation of a cluster of MERS cases in a nonhealth care–associated setting, 18 (2.2%) of 828 contacts were positive for MERS-CoV infections. This rate was similar to household contact study of 4.3%.

Intrahospital Transmission
Health care–associated infection is the hallmark of the transmission of MERS-CoV between patients and from patients to HCWs. Of the factors contributing to intrahospital transmission is the occurrence of superspreading events. In the outbreak in the Republic of Korea, three patients were epidemiologically connected to 73% of the transmissions and each infected 23, 28, and 85 individuals. In addition, superspreader phenomena also occurred in the first reported outbreak in Al-Hasa, Saudi Arabia. A recent systematic review outlined the contributing factors to health care–associated MERS-CoV transmissions and included: absent physical barriers between beds, inadequate isolation of suspected MERS patients, lack of isolation and negative pressure rooms, unfamiliarity and underrecognition of MERS infection, insufficient compliance with infection control measures, aerosol generating procedures, presence of multiple friends and family members in the patient’s room, and the phenomena of “medical shopping.” HCWs may act as contributors to the spread of MERS-CoV infection. In one study, MERS-CoV PCR was positive in 4.5% among exposed HCWs and another study showed 15 (1.3%) of 1,169 HCWs were positive by PCR and 5 (0.68%) of 737 HCWs were positive by serology. Other studies showed none of 38 HCWs was positive by serology and none of 48 contacts was positive. In Korea, 36 (19.9%) of 181 confirmed MERS-CoV cases were HCWs. However, studies had showed that most positive HCWs were asymptomatic or had mild disease. Although major hospital outbreaks were thought to be linked to intrahospital transmission of MERS-CoV, MERS-CoV genome sequence in these outbreaks showed multiple introductions of the virus with human-to-human transmissions. There were three distinct MERS-CoV genotypes.

Seasonality of MERS-CoV
The emergence of MERS-CoV had led to many speculations regarding the seasonality of this disease and initially thought to occur mostly in March–May and September–November. One reason for such a significant increase in April–May 2014 was a large outbreak in Jeddah, Saudi Arabia. However, seasonal variation may be the result of seasonality in the calving of dromedaries in November and March. Such a concept was studied and it was found that the prevalence of MERS-CoV was higher in camels in the winter (71.5%) than the summer season (62%). Looking at all MERS-CoV cases from 2012 to 2016, the mean monthly cases were

| Table 1 (Continued) |

| MERS-CoV | SARS-CoV |
|----------|----------|
| Thrombocytopenia (<140 × 10^9/L) | 36% | 40–45% |
| Elevated LDH | 48% | 50–71% |
| Elevated ALT | 11% | 20–30% |
| Elevated AST | 14% | 20–30% |
| Ventilatory support required | 80% | 14–20% |

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CFR, case fatality rate; CI, confidence interval; CXR, chest X-ray; KSA, Kingdom of Saudi Arabia; LDH, lactate dehydrogenase; MERS-CoV, Middle East respiratory syndrome coronavirus; SARS-CoV, severe acute respiratory syndrome coronavirus.

Source: Reproduced with permission from Hui et al.161
Therapeutic Options

Currently, there is no approved therapy for MERS-CoV infection. Studies showed superiority of interferon (IFN)-β compared with other IFN types and that polyethylene glycol IFN-α had excellent cytopathic inhibitory effect. In addition, the combination of IFN-α2b and ribavirin showed augmentation of action and lower concentrations of IFN-α2b and ribavirin were required. However, the data from clinical use of these two agents in retrospective studies showed no therapeutic advantages of these on survival of patients. A retrospective analysis showed that using IFN to treat patients with positive MERS-CoV RT-PCR was associated with a case fatality rate of 90% compared with 44% in those with negative MERS-CoV RT-PCR test. Another study showed survival rates of 78.3, 75, and 68.4% using IFN-β, IFN-α, and ribavirin, respectively. The use of the antiretroviral therapy for MERS-CoV was tried using pegylated IFN, ribavirin, and lopinavir/ritonavir and another eight patients received mycophenolate mofetil and the latter patients survived. A randomized controlled trial using a combination of lopinavir–ritonavir and IFN-β1b is being conducted.

Seroprevalence of MERS-CoV

Although MERS-CoV PCR testing is the main methodology for the diagnosis of MERS-CoV infection, serologic tests confirmed 8 (6.4%) of 124 Jordanian contacts who were positive. Seroprevalence of 356 abattoir workers and blood donors found that 8 (2.2%) were weakly positive by immunofluorescence assay (IFA), and none was had positive neutralization titers. A seroprevalence study found none of 268 children with respiratory tract infections to be positive. In an evaluation of 280 household contacts, 12 (4.3%) were probable cases by serology. However, in a population-based survey of 10,000 samples, the seroprevalence was 0.15% and the camel shepherd and abattoir workers had 17- and 26-fold increase in seroprevalence in comparison to the general population.

Infection Control

MERS-CoV is stable in the environment and can survive on plastic and steel for up to 48 hours at lower temperature and humidity. However, MERS-CoV is less viable at higher temperature and humidity. This finding was confirmed by another study where a temperature of 65°C had a strong negative effect on viral infectivity compared with a temperature of 25°C. In the hospital setting, WHO advocates contact and droplet precautions with airborne isolation when dealing with aerosol-generating procedures. However, both the United States and the European Centre for Disease Prevention and Control recommend the use of airborne infection isolation precautions.

MERS and Camel Connections

In a recent study from Egypt, Senegal, Tunisia, Uganda, Jordan, Saudi Arabia, and Iraq, MERS-CoV was detected in camels using either PCR or serology. The positivity rate using PCR ranged from 0% in Uganda, Jordan, and Iraq to 3.1% in Saudi Arabia, 5.5% in Senegal, and 8.2% in Egypt. It was shown that seropositivity is very high (84.5%) among tested camels compared with PCR positivity of 3.8%. Studies from Saudi Arabia showed either no significant difference in seropositivity of MERS-CoV in camels in different regions or had detected variable seropositivity to MERS-CoV (37–100%). It is worth mentioning that Somalia and Sudan are the main source of imported camels into Saudi Arabia.

The seroprevalence of MERS-CoV is lower (30.3%) in juvenile camels (<2 years of age) compared with adult camels (82.6%) as described in the previous studies. Also, the detection rate of MERS-CoV RNA by PCR is higher in adults (16.1%) compared with juvenile camels (1.7%). What is unusual is the ability of MERS-CoV to causes reinfection of camels in the presence of antibodies. Another important finding of MERS-CoV in camels is that camels rarely show signs of infection. Although it has been postulated that drinking camel milk is one of the key sources of infection in the Arabian peninsula, a study found no MERS-CoV in the urine of naturally infected camels.

Conclusion

Emerging respiratory viruses, specially MERS-CoV, continue to challenge the public health infrastructure of countries of the Arabian Peninsula with the risk of transmission and outbreaks in other countries though travel. Although it is still debated by some, bats appear to be the common natural source of both SARS and MERS. There are considerable similarities in the clinical features of both MERS-CoV and SARS-CoV, but MERS tends to progress much faster to respiratory failure than SARS. Although SARS-CoV clinical cases disappeared since mid-2003, both MERS-CoV and SARS-CoV are still listed as priority pathogens by the WHO research and development blueprint. The case fatality rate of MERS-CoV is much higher and likely related to older age and comorbid illness of the sporadic cases. Several gaps continue in our knowledge about disease prevention and treatment, and more studies are needed to understand the pathogenesis, viral kinetics, mode of disease transmission, any other intermediary source, and treatment options of MERS to guide public health infection control measures and treatment.

Conflict of Interest

None declared.
References

1. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348(20): 1986–1994
2. Shaw K. The 2003 SARS outbreak and its impact on infection control practices. Public Health 2006;120(01):8–14
3. Zaki AM, van Boeheimen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367(19):1814–1820
4. Corman VM, Eckerle I, Bleicker T, et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill 2012;17(39):17
5. de Groot RJ, Baker SC, Baric RS, et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol 2013;87(14):7790–7792
6. Al-Tawfiq JA, Zumla A, MemishZA. Coronaviruses: severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus in travelers. Curr Opin Infect Dis 2014;27(05):411–417
7. Al-Tawfiq JA, Zumla A, Gautret P, et al. Surveillance for emerging respiratory viruses. Lancet Infect Dis 2014;14(10):992–1000
8. Wolfe ND, Dunavan CP, Diamond J. Origins of major human infectious diseases. Nature 2007;447(7142):279–283
9. Tyrrell DA, Bynoe ML. Cultivation of a novel type of common cold virus in organ cultures. BMJ 1965;1(5448):1467–1470
10. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 2015;28(02):465–522
11. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348(20):1967–1976
12. Kuiken T, Fouchier RA, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003;362(9380):263–270
13. van Boeimeen S, de Graaf M, Lauber C, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 2012;3(06):e00473–e12
14. Cheng VC, Lau SK, Woo PC, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 2007;20(04):660–694
15. Ksiazek TG, Erdman D, Goldsmith CS, et al; SARS Working Group. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348(20):1953–1966
16. Leung GM, Hedley AJ, Hol L-M, et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann Intern Med 2004;141(09):662–673
17. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348(20):1977–1985
18. Poutanen SM, Low DE, Henry B, et al; National Microbiology Laboratory, Canada; Canadian Severe Acute Respiratory Syndrome Study Team. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003;348(20):1995–2005
19. Centers for Disease Control and Prevention (CDC). Outbreak of severe acute respiratory syndrome–worldwide, 2003. MMWR Morb Mortal Wkly Rep 2003;52(11):226–228
20. Centers for Disease Control and Prevention (CDC). Preliminary clinical description of severe acute respiratory syndrome. MMWR Morb Mortal Wkly Rep 2003;52(12):255–256
21. Centers for Disease Control and Prevention (CDC). Update: severe acute respiratory syndrome–United States, June 4, 2003. MMWR Morb Mortal Wkly Rep 2003;52(22):525–526
22. Centers for Disease Control and Prevention (CDC). Severe acute respiratory syndrome (SARS) and coronavirus testing–United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52(14):297–302
23. Centers for Disease Control and Prevention (CDC). Severe acute respiratory syndrome–Singapore, 2003. MMWR Morb Mortal Wkly Rep 2003;52(18):405–411
24. Parashar UD, Anderson LJ. Severe acute respiratory syndrome: review and lessons of the 2003 outbreak. Int J Epidemiol 2004;33(04):628–634
25. World Health Organization (WHO). Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. WHO; 2015
26. Chiang C-H, Shih J-F, Su W-J, Pereng R-P. Eight-month prospective study of 14 patients with hospital-acquired severe acute respiratory syndrome. Mayo Clin Proc 2004;79(11):1372–1379
27. Sung JJ, Wu A, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 2004;59(05):414–420
28. Hsu L-Y, Lee C-C, Green JA, et al. Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis 2003;9(06):713–717
29. Peiris JS, Chu CM, Cheng VC, et al; HKU1/IUC SARS Study Group. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003;361(9371):1767–1772
30. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. [see comment] [erratum appears in JAMA 2003 Jul 16;290(3):334]JAMA 2003;289(21):2801–2809
31. Kwan YW, Leung CW, Chu MC. Diarrhoea as the presenting sign in an adolescent suffering from severe acute respiratory syndrome. Eur J Pediatr 2005;164(04):227–230
32. Nuttall I, Dye C. Epidemiology. The SARS wake-up call. Science 2003;339(6125):1287–1288
33. Nuttall I, Dye C. Epidemiology. The SARS wake-up call. Science 2003;339(6125):1287–1288
34. Cameron PA, Rainer TH. SARS: a wake up call for a health care system under stress. Emerg Med (Fremantle) 2003;15(3–6):409–412
35. Lapinsky SE, Granton JT. Critical care lessons from severe acute respiratory syndrome. Curr Opin Crit Care 2004;10(01):53–58
36. Leung CW, Chiu WK. Clinical picture, diagnosis, treatment and outcome of severe acute respiratory syndrome (SARS) in children. Paediatr Respir Rev 2004;5(04):275–288
37. Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003;302(5643):276–278
38. Centers for Disease Control and Prevention (CDC). Prevalence of IgG antibody to SARS-associated coronavirus in animal traders–Guangdong Province, China, 2003. MMWR Morb Mortal Wkly Rep 2003;52(41):986–987
39. Tsai M-H, Lin T-Y, Chiu C-H, et al. Seroprevalence of SARS coronavirus among residents near a hospital with a nosocomial outbreak. J Formos Med Assoc 2008;107(11):885–891
40. Ip M, Chan PK, Lee N, et al. Seroprevalence of antibody to severe acute respiratory syndrome (SARS)-associated coronavirus among health care workers in SARS and non-SARS medical wards. Clin Infect Dis 2004;38(12):e116–e118
41. Leung GM, Lim WW, Ho LM, et al. Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups. Epidemiol Infect 2006;134(02):211–221
42. Momattin H, Mohammed K, Zumla A, Memish ZA, Al-TawfiqJA. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)–possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis 2013;17(10):e792–e798
43. Memish ZA, Mishra N, Olival KJ, et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis 2013;19(11):1819–1823
44 Reusken CB, Haagmans BL, Müller MA, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 2013;13(10):859–866
45 Reusken CB, Ababneh M, Raj VS, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveill 2013;18(50):20662
46 Hemida MG, Perera RA, Wang P, et al. Middle East respiratory syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. Euro Surveill 2013;18(50):20659
47 Alexandersen S, Kobinger GP, Soule G, Wernery U. Middle East respiratory syndrome coronavirus antibody reactors among camels in Dubai, United Arab Emirates, in 2005. Transbound Emerg Dis 2014;61(02):105–108
48 Reusken CB, Messadi L, Feyisa A, et al. Geographic distribution of MERS coronavirus among dromedary camels, Africa. Emerg Infect Dis 2014;20(08):1370–1374
49 Nowotny N, Kolodziejek J. Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels, Oman, 2013. Euro Surveill 2014;19(16):20781
50 Corman VM, Jores J, Meyer B, et al. Antibodies against MERS coronavirus in dromedary camels, Kenya, 1992-2013. Emerg Infect Dis 2014;20(08):1319–1322
51 Hemida MG, Perera RA, Al Jassim RA, et al. Seroepidemiology of Middle East respiratory syndrome (MERS) coronavirus in Saudi Arabia (1993) and Australia (2014) and characterisation of assay specificity. Euro Surveill 2014;19(23):19
52 Alagaili AN, Briese T, Mishra N, et al. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio 2014;5(02):e00884–e14
53 Hemida MG, Afnan A, Chu DK, et al. Longitudinal study of Middle East respiratory syndrome coronavirus infection in dromedary camel herds in Saudi Arabia, 2014-2015. Emerg Microbes Infect 2017;6(06):e56
54 Wernery U, Corman VM, Wong EY, et al. Acute Middle East respiratory syndrome coronavirus infection in livestock Dromedaries, Dubai, 2014. Emerg Infect Dis 2015;21(06):1019–1022
55 Khalafalla AL, Lu X, Al-Mubarak AL, Dalab AH, Al-Busadah KA, Erdman DD. MERS-CoV in upper respiratory tract and lungs of dromedary camels, Saudi Arabia, 2013-2014. Emerg Infect Dis 2015;21(07):1153–1158
56 Farag EA, Reusken CB, Haagmans BL, et al. High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014. Infect Ecol Epidemiol 2015;5:28305
57 Raj VS, Farag EA, Reusken CB, et al. Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014. Emerg Infect Dis 2014;20(08):1339–1342
58 Yusof MF, Eltahir YM, Serhan WS, et al. Prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Abu Dhabi Emirate, United Arab Emirates. Virus Genes 2015;50(03):509–513
59 Hemida MG, Chu DK, Poon LL, et al. MERS coronavirus in dromedary camel herd, Saudi Arabia. Emerg Infect Dis 2014;20(07):1231–1234
60 Briese T, Mishra N, Jain K, et al. Middle East respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through whole-genome analysis and virus cultured from dromedary camels in Saudi Arabia. MBio 2014;5(03):e01146–e14
61 Haagmans BL, Al Dhahiry SH, Reusken CB, et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis 2014;14(02):140–145
62 Memish ZA, Cotten M, Meyer B, et al. Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013. Emerg Infect Dis 2014;20(06):1012–1015
63 Azhar EI, El-Kafrawy SA, Farraj SA, et al. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 2014;370(26):2499–2505
64 Al Hammadi ZM, Chu DK, Eltahir YM, et al. Asymptomatic MERS-CoV infection in humans possibly linked to infected dromedaries imported from Oman to United Arab Emirates, May 2015. Emerg Infect Dis 2015;21(12):2197–2200
65 Lau SKP, Wong ACP, Lau TCK, Woo PCY. Molecular evolution of MERS coronavirus: dromedaries as a recent intermediate host or long-time animal reservoir? Int J Mol Sci 2017;18(10):E2138
66 Cotten M, Watson SJ, Zumla AL, et al. Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus. MBio 2014;5(01):e01062–e13
67 Cotten M, Watson SJ, Kellam P, et al. Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study. Lancet 2013;382(9909):1993–2002
68 Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother 2015;70(07):2129–2132
69 Assiri A, McGeer A, Perl TM, et al; KSA MERS-CoV Investigation Team. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013;369(05):407–416
70 Saad M, Omran AS, Baig K, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 2014;29:301–306
71 Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013;13(09):752–761
72 Al-Tawfiq JA, Hinedi K, Ghandour J, et al. Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients. Clin Infect Dis 2014;59(02):160–165
73 Arabi YM, Arifi AA, Balkhy HH, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 2014;160(06):389–397
74 Fagbo SF, Skaklni L, Chu DK, et al. Molecular epidemiology of hospital outbreak of Middle East respiratory syndrome, Riyadh, Saudi Arabia, 2014. Emerg Infect Dis 2015;21(11):1981–1988
75 Al-Hameed F, Wahla AS, Siddiqui S, et al. Characteristics and outcomes of Middle East respiratory syndrome coronavirus patients admitted to an intensive care unit in Jeddah, Saudi Arabia. J Intensive Care Med 2016;31(05):344–348
76 Al-Tawfiq JA, Alfaraj SH, Altuwaijri TA, Memish ZA. A cohort-study of patients suspected for MERS-CoV in a referral hospital in Saudi Arabia. J Infect 2017;75(04):378–379
77 The WHO MERS-CoV Research Group. State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans. PLoS Curr 2013;5 pii: e currents. outbreaks.0b71f919e5352e74f81ad85fa30
78 Nam HS, Park JW, Ki M, Yeon M-Y, Kim J, Kim SW. High fatality rates and associated factors in two hospital outbreaks of MERS in Daejeon, the Republic of Korea. Infect Chemother 2014;36:1322–1327
79 Al Hammadi ZM, Chu DK, Al-Hameed F, et al. MERS-CoV Epidemiology and Clinical Disease. Al-Tawfiq, Memish
Al-Tawfiq, Memish

Buchholz U, Müller MA, Nitsche A, et al. Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012. Euro Surveill 2013;18(08):18

Seventy-three (73) MERS-CoV coronavirus cases globally—is the epidemic changing? Euro Surveill 2013;18(39):18

Mohd HA, Memish ZA, Alfaraj SH, et al. Predictors of MERS-CoV infection: a large case control study of patients presenting with ILL at a MERS-CoV referral hospital in Saudi Arabia. Travel Med Infect Dis 2016;14(05):464–470

Garbati MA, Fagbo SF, Fang VJ, et al. A comparative study of clinical presentation and risk factors for adverse outcome in patients hospitalised with acute respiratory disease due to MERS coronavirus or other causes. PLoS One 2016;11(11):e0165978

Command and Control Center Ministry of Health Kingdom of Saudi Arabia Scientific Advisory Board. Infection Prevention and Control Guidelines for the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection, 4th Edition. 2017. Available at: http://www.moh.gov.sa/en/epidets/Infection/Documents/Guidelines-MERS-CoV.PDF. Accessed May 12, 2017

Saeed AA, Abedi GR, Alzahrani AG, et al. Surveillance and testing for Middle East respiratory syndrome coronavirus, Saudi Arabia, April 2015-February 2016. Emerg Infect Dis 2017;23(04):682–685

Alfaraj SH, Al-Tawfiq JA, Gautret P, Alenazi MG, Asiri AY, Memish ZA. Evaluation of visual triage for screening of Middle East respiratory syndrome coronavirus patients. New Microbes New Infect 2018;26:49–52

Ahmed AE. The predictors of 3- and 30-day mortality in 660 MERS-CoV patients. BMC Infect Dis 2017;17(01):615

Arabi YM, Mandourah Y, Al-Hameed F, et al; Saudi Critical Care Trial Group. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 2018;197(06):757–767

Alfaraj SH, Al-Tawfiq JA, Assiri AY, Alzahrani NA, Alanazi AA, Memish ZA. Clinical predictors of mortality of Middle East respiratory syndrome coronavirus (MERS-CoV) infection: a cohort study. Travel Med Infect Dis 2019;29:48–50

Cha R-H, Joh J-S, Jeong I, et al; Critical Care Team of National Hospital, October-November 2012. Euro Surveill 2013;18(08):18

Drosten C, Meier B, Müller MA, et al. Transmission of MERS-coronavirus in household contacts. N Engl J Med 2014;371(09):828–835

Drosten C, Seilmaier M, Corman VM, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 2013;13(09):745–751

Omranis AS, Matin MA, Haddad Q, Al-Nakhli D, Memish ZA, Albarrak AM. A family cluster of Middle East respiratory syndrome coronavirus infections related to a likely unrecognized asymptomatic or mild case. Int J Infect Dis 2013;17(09):e668–e672

Rahman A, Sarkar A. Risk factors for fatal Middle East respiratory syndrome coronavirus infections in Saudi Arabia: analysis of the WHO line list, 2013–2018. Am J Public Health 2019;109(09):1288–1293

Hakawi A, Rose EB, Biggs HM, et al. Middle East respiratory syndrome coronavirus, Saudi Arabia, 2017–2018. Emerg Infect Dis 2019;25(11):2149–2151

Van Kirkhove MD, Alaswad S, Assiri A, et al. Transmissibility of MERS-CoV infection in closed setting, Riyadh, Saudi Arabia, 2015. Emerg Infect Dis 2019;25(10):1802–1809

Drosten C, Muth D, Corman VM, et al. An observational, laboratory-based study of outbreaks of Middle East respiratory syndrome coronavirus in Jeddah and Riyadh, kingdom of Saudi Arabia, 2014. Clin Infect Dis 2015;60(03):369–377

Memish ZA, Al-Tawfiq JA, Alhakeem RF, et al. Middle East respiratory syndrome coronavirus (MERS-CoV): a cluster analysis with implications for global management of suspected cases. Travel Med Infect Dis 2015;13(04):311–314

El Bushra HE, Abdalla MN, Al Arbash H, et al. An outbreak of Middle East respiratory syndrome (MERS) due to coronavirus in Al-Hasa Region, Saudi Arabia, 2015. East Mediterr Health J 2016;22(07):468–475

Balkhy HH, Alenazi TH, Alshamrani MM, et al. Notes from the field: nosocomial outbreak of Middle East respiratory syndrome coronavirus in a large tertiary care hospital–Riyadh, Saudi Arabia, 2015. MMWR Morb Mortal Wkly Rep 2016;65(06):163–164

Balkhy HH, Alenazi TH, Alshamrani MM, et al. Description of a hospital outbreak of Middle East respiratory syndrome in a large tertiary care hospital in Saudi Arabia. Infect Control Hosp Epidemiol 2016;37(10):1147–1155

Assiri AM, Biggs HM, Abedi GR, et al. Increase in Middle East respiratory syndrome–coronavirus cases in Saudi Arabia linked to hospital outbreak with continued circulation of recombinant virus, July 1-August 31, 2015. Open Forum Infect Dis 2016;3:ofw165

Nazer RI. Outbreak of Middle East respiratory syndrome–coronavirus causes high fatality after cardiac operations. Ann Thorac Surg 2017;104(02):e127–e129

Assiri A, Abedi GR, Bin Saeed AA, et al. Multifacility outbreak of Middle East respiratory syndrome in Taif, Saudi Arabia. Emerg Infect Dis 2016;22(01):32–40

Hunter JC, Nguyen D, Aden B, et al. Transmission of Middle East respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi. Emerg Infect Dis 2016;22(04):647–656

Cauchemez S, Van Kerkhove MD, Riley S, Donnelly CA, Fraser C, Ferguson NM. Transmission scenarios for Middle East respiratory syndrome coronavirus (MERS-CoV) and how to tell them apart. Euro Surveill 2013;18(24):20503

Cauchemez S, Fraser C, Van Kerkhove MD, et al. Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility. Lancet Infect Dis 2014;14(01):50–56

Chowell G, Abdizirak F, Lee S, et al. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC Med 2015;13:210
WHO. Infection prevention and control of epidemic-and pandemic prone acute respiratory infections in health care. WHO2015

World Health Organization (WHO). Infection prevention and control of epidemic-and pandemic prone acute respiratory infections in health care. WHO2015

CDC. Interim Infection Prevention and Control Recommendations for Hospitalized Patients with Middle East Respiratory Syndrome Coronavirus (MERS-CoV). 2015. Available at: https://www.cdc.gov/coronavirus/mers/infection-prevention-control.html. Accessed March 9, 2017

Kandeil A, Gomaa M, Nageh A, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Africa and Middle East. Viruses 2019;11(08):717

Ali MA, Shehata MM, Gomaa MR, et al. Systematic, active surveillance for Middle East respiratory syndrome coronavirus in camels in Egypt. Emerg Microbes Infect 2017; 6(01):e1

Kasem S, Qasim I, Al-Hufofi A, et al. Cross-sectional study of MERS-CoV-specific RNA and antibodies in animals that have had contact with MERS patients in Saudi Arabia. J Infect Public Health 2018;11(03):331–338

Chu DK, Poon LL, Gomaa MM, et al. MERS coronaviruses in dromedary camels, Egypt. Emerg Infect Dis 2014;20(06):1049–1053

Farag EA, Haagmans BL, Al-Romaihi H, et al. Failure to detect MERS-CoV RNA in urine of naturally infected dromedary camels. Zoonoses Public Health 2019;66(05):437–438

Hui DS, Memish ZA, Zumla A. Severe acute respiratory syndrome versus the Middle East respiratory syndrome. Curr Opin Pulm Med 2014;20:233–241